Dr. Murthy on the Clinical Implications of Tucatinib Approval in HER2+ Breast Cancer
In Partnership With:
Rashmi Murthy, MD, MBE, discusses the data that led to the approval of the tucatinib triplet, the clinical implications of the approval on practice, and the next steps for research with the agent.
Rashmi Murthy, MD, MBE, assistant professor in the Department of Breast Medical Oncology of the Division of Cancer Medicine at The University of Texas MD Anderson Cancer Center, discusses the data that led to the approval of the tucatinib triplet, the clinical implications of the approval on practice, and the next steps for research with the agent.
Please visit www.OncLive.com to watch the entitreity of the MJH Life Sciences News Network, which provides the latest news across a variety of healthcare specialties, and a number of interviews with experts in the medical field, many of which are focused on the ongoing COVID-19 pandemic.
